Cancer Targets refer to a series of targets involved in targeted cancer therapies. Targeted cancer therapies, also called molecularly targeted therapies, are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression, and spread of cancer.
Targeted therapies differ from standard chemotherapy. The primary difference is that targeted therapies act on specific molecular targets that are associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells. Targeted therapies currently focus on anticancer drug development. They are a cornerstone of precision medicine, a form of medicine that uses information about a person’s genes and proteins to prevent, diagnose, and treat disease.
The development of targeted therapies requires the identification of good targets—that is, targets that play a key role in cancer cell growth and survival. Currently, CUSABIO have developed several proteins of cancer targets with high purity. All of them have validated by activity and endotoxin. They can give your assistance to drug development.
Measured by its binding ability in a functional ELISA. Immobilized Human EPHA3 (CSB-MP007723HU) at 2 μg/ml can bind human EFNA5, the EC50 of human EFNA5 protein is 0.8674-1.119 ng/ml
Human EPHA3 protein his tag (CSB-MP007723HU) captured on COOH chip can bind Human EFNA5 protein Fc tag (CSB-MP007464HU) with an affinity constant of 13.8 pM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized GH1 at 1 μg/ml can bind human PRLR (CSB-MP018727HU1), the EC50 of the protein is 60.71-69.65 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized GH1 at 1 μg/ml can bind human GHR (CSB-MP009411HU), the EC50 of the protein is 19.28-25.29 ng/ml.